Neoleukin Therapeutics In... (NLTX)
NASDAQ: NLTX
· Real-Time Price · USD
3.49
0.05 (1.45%)
At close: Dec 18, 2023, 10:00 PM
Neoleukin Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -126M | -107.87M | -55.63M | -34.26M | -42.81M | -56.41M | -57.56M | -59.28M | -61.65M | -61.09M | -60.69M | -58.16M | -44.97M | -39.59M |
Depreciation & Amortization | 4.34M | 3.96M | 2.45M | 2.01M | 2.22M | 2.57M | 2.61M | 2.6M | 2.6M | 2.43M | 2.28M | 2.1M | 1.95M | 1.63M |
Stock-Based Compensation | 16M | 12.13M | 5.83M | 3.73M | 5.59M | 7.57M | 8.83M | 9.8M | 10.98M | 11.58M | 11.56M | 10.78M | 9.26M | 7.36M |
Other Working Capital | -226K | -226K | n/a | -1.82M | -1.82M | -1.82M | -3.13M | -1.58M | -1.58M | -1.58M | -1.21M | -2.44M | -2.46M | -3.03M |
Other Non-Cash Items | -12.98M | -13.54M | -5.76M | 1.26M | 1.81M | 2.7M | -376K | -697K | -697K | -700K | -700K | 966K | 994K | 1.27M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 700K | 700K | 700K | 700K | -966K | -966K | -966K |
Change in Working Capital | 6.76M | 7.02M | n/a | -5.03M | -4.12M | -980K | 885K | 36K | 1.76M | -1.21M | -700K | 664K | -2.24M | -1.21M |
Operating Cash Flow | -114.81M | -98.31M | -53.11M | -32.28M | -37.3M | -44.55M | -45.61M | -46.84M | -46.31M | -48.29M | -47.56M | -44.62M | -35.98M | -31.49M |
Capital Expenditures | -1.6M | -817K | -692K | -655K | -977K | -1.08M | -1.11M | -1.4M | -1.67M | -2.63M | -3.26M | -3.52M | -3.42M | -3.2M |
Cash Acquisitions | n/a | n/a | n/a | -39.07M | -39.07M | -39.07M | -39.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -212.23M | -159.88M | -80.2M | -117.81M | -123.73M | -96.83M | -68.46M | -42.53M | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | -158.5M | -123.5M | n/a | 133.5M | 113.5M | 89M | 49.5M | 15M | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 172.72M | 128.02M | 58.25M | 41.18M | 41.18M | n/a | n/a | -39.07M | -39.07M | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -199.61M | -156.18M | -22.64M | 17.15M | -9.09M | -47.98M | -59.13M | -68M | -40.73M | -2.63M | -3.26M | -3.52M | -3.42M | -3.2M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | 82K | 82K | 82K | 82K | 372K | 372K | 372K | 372K | 199K | 199K | 199K |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -783K | -783K | -783K | -783K | n/a | n/a | n/a |
Other Financial Acitivies | 179.32M | 179.31M | -5.73M | -343K | -394K | -38K | 161K | 1.03M | 1.12M | 1.37M | 1.51M | 1.91M | 74.04M | 74.03M |
Financial Cash Flow | 178.74M | 178.73M | -5.99M | -343K | -394K | -38K | 161K | 250K | 334K | 583K | 732K | 1.91M | 74.04M | 74.03M |
Net Cash Flow | 86.61M | 146.54M | 30.6M | -15.48M | -46.79M | -92.56M | -104.58M | -114.59M | -86.71M | -50.33M | -50.09M | -46.23M | 34.64M | 39.34M |
Free Cash Flow | -116.41M | -99.13M | -53.8M | -32.94M | -38.28M | -45.63M | -46.72M | -48.24M | -47.98M | -50.92M | -50.82M | -48.14M | -39.4M | -34.69M |